From Yahoo Finance: 2025-06-11 20:03:00

Avidity Biosciences, Inc. (NASDAQ:RNA) is highlighted as one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James gives Avidity Biosciences, Inc. (NASDAQ:RNA) a Strong Buy rating and a $65 price target, emphasizing the potential of its antibody oligonucleotide conjugate (AOC) platform.

Raymond James believes in the revolutionary potential of Avidity Biosciences, Inc. (NASDAQ:RNA)’s AOC platform, with Del-Zota as a top candidate for approval. The firm sees favorable risk/reward in the biotech sector and values early-stage assets for higher returns, placing confidence in the platform’s first potential approved medicine.

Avidity Biosciences, Inc. (NASDAQ:RNA) is recognized for its development of Antibody Oligonucleotide Conjugates (AOCs) in the RNA treatment field. Raymond James sets a $65 price target, reflecting faith in the platform’s innovative approach and potential for success.

While Avidity Biosciences, Inc. (NASDAQ:RNA) shows promise in the biopharmaceutical sector, there are alternative investment opportunities in AI stocks with greater upside potential. For insights on undervalued AI stocks and market trends, refer to the free report on the best short-term AI stock for informed investment decisions.

Read more: Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James